Abstract
Several investigations have presented evidence that amylin inhibits insulin secretion and induces insulin resistance both in vitro and in viva. However, basal and postmeal amylin concentrations proved similar in non- insulin-dependent diabetes mellitus (NIDDM) patients and controls. Since hyperglycemia may alter both amylin and insulin secretion, we examined basal and glucose-stimulated amylin secretion in eight glucose-tolerant, insulin- resistant Mexican-American subject with both parents affected with NIDDM (offspring) end correlated the findings with the insulin sensitivity data acquired by an insulin clamp. Eight offspring and eight Mexican-Americans without any family history of diabetes (controls) underwent measurement of fat free mass (3H2O dilution method), 180-minutes, 75-g oral glucose tolerance test (OGTT), and 40-mU/m2, 180-minute euglycemic insulin clamp associated with 3H-glucose infusion and indirect calorimetry. Fasting amylin was significantly increased in offspring versus controls (11.5 ± 1.4 v 7.0 ± 0.8 pmol/L, P < .05). After glucose ingestion, both total (3,073 ± 257 v 1.870 ± 202 pmol · L-1 · min-1, P < .01) and incremental (1,075 ± 170 v 518 ± 124 pmol · L-1 · min-1, P < .05) areas under the curve (AUCs) of amylin concentration were significantly greater in offspring. The amylin to insulin molar ratio was similar in offspring and controls at all time points. Basal and postglucose insulin and C-peptide concentrations were significantly increased in the offspring. No correlation was found between fasting amylin, postglucose amylin AUC or IRUC, and any measured parameter of glucose metabolism during a euglycemic-hyperinsulinemic clamp (total glucose disposal, 7.21 ± 0.73 v 11.03 ± 0.54, P < 001; nonoxidative glucose disposal 3.17 ± 0.59 v 6.33 ± 0.56, P < .002; glucose oxidation 4.05 p 0.46 v 4.71 ± 0.21, P = NS; hepatic glucose production, 0.29 ± 0.16 v 0.01 ± 0.11, P = NS; all mg · min-1 · kg-1 fat-free mass, offspring v controls. In conclusion, these data do not support a causal role for amylin in the genesis of insulin resistance in NIDDM.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1157-1161 |
| Number of pages | 5 |
| Journal | Metabolism: Clinical and Experimental |
| Volume | 46 |
| Issue number | 10 |
| DOIs | |
| State | Published - 1997 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Endocrinology
- Endocrinology, Diabetes and Metabolism
Cite this
Hyperamylinemia is associated with hyperinsulinemia in the glucose- tolerant, insulin-resistant offspring of two Mexican-American non-insulin- dependent diabetic parents. / Gulli, Giovanni; Rossetti, Luciano; Defronzo, Ralph A.
In: Metabolism: Clinical and Experimental, Vol. 46, No. 10, 1997, p. 1157-1161.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Hyperamylinemia is associated with hyperinsulinemia in the glucose- tolerant, insulin-resistant offspring of two Mexican-American non-insulin- dependent diabetic parents
AU - Gulli, Giovanni
AU - Rossetti, Luciano
AU - Defronzo, Ralph A
PY - 1997
Y1 - 1997
N2 - Several investigations have presented evidence that amylin inhibits insulin secretion and induces insulin resistance both in vitro and in viva. However, basal and postmeal amylin concentrations proved similar in non- insulin-dependent diabetes mellitus (NIDDM) patients and controls. Since hyperglycemia may alter both amylin and insulin secretion, we examined basal and glucose-stimulated amylin secretion in eight glucose-tolerant, insulin- resistant Mexican-American subject with both parents affected with NIDDM (offspring) end correlated the findings with the insulin sensitivity data acquired by an insulin clamp. Eight offspring and eight Mexican-Americans without any family history of diabetes (controls) underwent measurement of fat free mass (3H2O dilution method), 180-minutes, 75-g oral glucose tolerance test (OGTT), and 40-mU/m2, 180-minute euglycemic insulin clamp associated with 3H-glucose infusion and indirect calorimetry. Fasting amylin was significantly increased in offspring versus controls (11.5 ± 1.4 v 7.0 ± 0.8 pmol/L, P < .05). After glucose ingestion, both total (3,073 ± 257 v 1.870 ± 202 pmol · L-1 · min-1, P < .01) and incremental (1,075 ± 170 v 518 ± 124 pmol · L-1 · min-1, P < .05) areas under the curve (AUCs) of amylin concentration were significantly greater in offspring. The amylin to insulin molar ratio was similar in offspring and controls at all time points. Basal and postglucose insulin and C-peptide concentrations were significantly increased in the offspring. No correlation was found between fasting amylin, postglucose amylin AUC or IRUC, and any measured parameter of glucose metabolism during a euglycemic-hyperinsulinemic clamp (total glucose disposal, 7.21 ± 0.73 v 11.03 ± 0.54, P < 001; nonoxidative glucose disposal 3.17 ± 0.59 v 6.33 ± 0.56, P < .002; glucose oxidation 4.05 p 0.46 v 4.71 ± 0.21, P = NS; hepatic glucose production, 0.29 ± 0.16 v 0.01 ± 0.11, P = NS; all mg · min-1 · kg-1 fat-free mass, offspring v controls. In conclusion, these data do not support a causal role for amylin in the genesis of insulin resistance in NIDDM.
AB - Several investigations have presented evidence that amylin inhibits insulin secretion and induces insulin resistance both in vitro and in viva. However, basal and postmeal amylin concentrations proved similar in non- insulin-dependent diabetes mellitus (NIDDM) patients and controls. Since hyperglycemia may alter both amylin and insulin secretion, we examined basal and glucose-stimulated amylin secretion in eight glucose-tolerant, insulin- resistant Mexican-American subject with both parents affected with NIDDM (offspring) end correlated the findings with the insulin sensitivity data acquired by an insulin clamp. Eight offspring and eight Mexican-Americans without any family history of diabetes (controls) underwent measurement of fat free mass (3H2O dilution method), 180-minutes, 75-g oral glucose tolerance test (OGTT), and 40-mU/m2, 180-minute euglycemic insulin clamp associated with 3H-glucose infusion and indirect calorimetry. Fasting amylin was significantly increased in offspring versus controls (11.5 ± 1.4 v 7.0 ± 0.8 pmol/L, P < .05). After glucose ingestion, both total (3,073 ± 257 v 1.870 ± 202 pmol · L-1 · min-1, P < .01) and incremental (1,075 ± 170 v 518 ± 124 pmol · L-1 · min-1, P < .05) areas under the curve (AUCs) of amylin concentration were significantly greater in offspring. The amylin to insulin molar ratio was similar in offspring and controls at all time points. Basal and postglucose insulin and C-peptide concentrations were significantly increased in the offspring. No correlation was found between fasting amylin, postglucose amylin AUC or IRUC, and any measured parameter of glucose metabolism during a euglycemic-hyperinsulinemic clamp (total glucose disposal, 7.21 ± 0.73 v 11.03 ± 0.54, P < 001; nonoxidative glucose disposal 3.17 ± 0.59 v 6.33 ± 0.56, P < .002; glucose oxidation 4.05 p 0.46 v 4.71 ± 0.21, P = NS; hepatic glucose production, 0.29 ± 0.16 v 0.01 ± 0.11, P = NS; all mg · min-1 · kg-1 fat-free mass, offspring v controls. In conclusion, these data do not support a causal role for amylin in the genesis of insulin resistance in NIDDM.
UR - http://www.scopus.com/inward/record.url?scp=0030882286&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030882286&partnerID=8YFLogxK
U2 - 10.1016/S0026-0495(97)90209-2
DO - 10.1016/S0026-0495(97)90209-2
M3 - Article
C2 - 9322799
AN - SCOPUS:0030882286
VL - 46
SP - 1157
EP - 1161
JO - Metabolism: Clinical and Experimental
JF - Metabolism: Clinical and Experimental
SN - 0026-0495
IS - 10
ER -